A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Sep 25, 2018

BLINCYTO® FOR DRIP INFUSION 35μg APPROVED IN JAPAN FOR THE TREATMENT OF RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

THE FIRST-AND-ONLY BISPECIFIC CD19-DIRECTED CD3 T CELL ENGAGER (BiTE®) IMMUNOTHERAPY

Amgen Astellas BioPharma K.K. (Headquarters, Tokyo; President and Representative Director: Steve Sugino, “Amgen Astellas”) and Astellas Pharma Inc. (Headquarters, Tokyo; President and CEO:...

Read more
Sep 25, 2018

Astellas Receives Positive CHMP Opinion for XTANDI^TM (enzalutamide) for Adult Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer

Results from the PROSPER trial show a median metastasis-free survival (MFS) of 36.6 months for enzalutamide plus androgen deprivation therapy (ADT) vs 14.7 months for men who received placebo plus ADT1

TOKYO and CHERTSEY, September 24, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that The Committee for Medicinal Products for...

Read more
Sep 21, 2018

Notice of Completion of Acquisition of Own Shares

Read more
Sep 21, 2018

Astellas Announces Approval in Japan for XOSPATA® 40 mg Tablets for the Treatment of FLT3mut+ Relapsed or Refractory AML

TOKYO, September 21, 2018 -Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that XOSPATA® Tablets 40 mg (generic name: gilteritinib), a...

Read more
Sep 20, 2018

Astellas Announces Positive Topline Results for Global Phase 3 Trial of Roxadustat in Chronic Kidney Disease (CKD) Patients with Anemia not on Dialysis

TOKYO, September 20, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that roxadustat, an inhibitor of hypoxia ¬inducible factor...

Read more
Sep 18, 2018

Astellas Announces Launch of Dafclir® Tablets for the Treatment of Infectious Enteritis Caused by Clostridium difficile in Japan

TOKYO, September 18, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that it has launched Dafclir® Tablets 200 mg (generic name:...

Read more
Sep 14, 2018

Gene Therapy Research Institution and Astellas Executes Option Agreement for Sporadic ALS Gene Therapy Program

TOKYO, September 14, 2018 –Gene Therapy Research Institution Co., Ltd. (head office: Kawasaki, Kanagawa; President: Katsuhito Asai, “GTRI”) and Astellas Pharma Inc. (TSE: 4503, head office:...

Read more
Sep 3, 2018

Astellas Announces Status of Acquisition of Own Shares

Read more
Aug 23, 2018

Pfizer and Astellas Amend Clinical Research Protocols for Two Phase 3 Trials of Enzalutamide in Patients with Hormone-Sensitive Prostate Cancer - Amendments accelerate anticipated primary completion dates for both ARCHES and EMBARK trials -

NEW YORK and TOKYO, August 22, 2018 –Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced amendments to the...

Read more
Aug 21, 2018

Approval of Linzess® Tablets 0.25 mg in Japan for Additional Indication of Chronic Constipation

TOKYO and CAMBRIDGE, Mass August 21, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) and Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD ,...

Read more
Aug 10, 2018

Astellas Announces Acquisition of Quethera - Acquisition furthers Astellas’ commitment to innovation in ophthalmology with addition of novel gene therapy program for glaucoma -

TOKYO, CAMBRIDGE (UK), August 10, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa,Ph.D., “Astellas”) and Quethera Limited (CEO: Peter Widdowson, Ph.D.,...

Read more
Aug 3, 2018

Application for Supplemental Indication Filed for Hypercholesterolemia Drug Repatha® SC Injection in Treating Statin-intolerant Patients

Amgen Astellas BioPharma K.K. (Headquarters, Tokyo; President and Representative Director: Steve Sugino, “Amgen Astellas”) and Astellas Pharma Inc. (Headquarters, Tokyo; President and CEO:...

Read more
Aug 1, 2018

Astellas Announces Status of Acquisition of Own Shares

Read more
Jul 17, 2018

U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC) - First and Only Oral Treatment FDA-Approved for Both Non-Metastatic and Metastatic CRPC -

TOKYO and NEW YORK, July 13, 2018 –Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug...

Read more
Jul 10, 2018

Seattle Genetics and Astellas Announce Progress in Enfortumab Vedotin Urothelial Cancer Clinical Development Program

-Enrollment of EV-201 Pivotal Trial Cohort Designed to Support Potential Expedited Registration Pathway in the U.S. Completed-

BOTHELL, Wash., and TOKYO, July 9, 2018 – Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced...

Read more
Jul 2, 2018

Astellas Announces Status of Acquisition of Own Shares

Read more
Jul 2, 2018

Astellas Received Approval for Dafclir® Tablets for the Treatment of Infectious Enteritis Caused by Clostridium difficile in Japan

TOKYO, July 2, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that it has received an approval for the marketing application of...

Read more
Jun 29, 2018

Results from Pivotal Phase 3 PROSPER Trial of XTANDI® (enzalutamide) in Men with Non-Metastatic Castration-Resistant Prostate Cancer Published in New England Journal of Medicine

Results show enzalutamide plus androgen deprivation therapy significantly reduced the risk of developing metastases or death by 71 percent compared to placebo plus androgen deprivation therapy

TOKYO, June 29, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that results from the pivotal Phase 3 PROSPER trial, which...

Read more
Jun 28, 2018

Astellas Named to FTSE4Good Index Series for the Seventh Consecutive Year

Tokyo, June 28, 2018 - Astellas Pharma Inc. (President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that it has been selected for the seventh consecutive year to be included in...

Read more
Jun 26, 2018

Astellas Announces Personnel Change

Astellas Announces Personnel Change

Read more
Jun 11, 2018

Astellas Announces Launch of XTANDI® Tablets in Japan for the Treatment of Castration-Resistant Prostate Cancer

TOKYO, June 11, 2018 - Astellas Pharma Inc. (President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that it launched 40 mg XTANDI® (generic name enzalutamide) Tablets and 80...

Read more
Jun 4, 2018

Astellas and Seattle Genetics Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy

-Updated Data from Phase 1 EV-101 Study Highlighted in ASCO 2018 Oral Presentation Support Rapid Development Program and Ongoing Pivotal Study-

TOKYO and BOTHELL, Wash. – June 3, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seattle Genetics, Inc. (Nasdaq: SGEN) today announced...

Read more
Jun 1, 2018

Astellas Announces Personnel Change

Astellas Announces Personnel Change

Read more
May 31, 2018

Astellas Announces Acquisition of Own Shares

Tokyo, May 31, 2018- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.) today announced that at the meeting of the Board of Directors held today, a resolution was adopted...

Read more
May 31, 2018

Astellas Submits Application for Approval of Peficitinib for Rheumatoid Arthritis (Including Prevention of Structural Joint Damage) in Patients Who Have an Inadequate Response to Conventional Therapies in Japan

TOKYO, May 31, 2018 - Astellas Pharma Inc. (President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that it has submitted an application for marketing approval of peficitinib...

Read more
May 31, 2018

Astellas and FibroGen Announce Topline Results from Double-Blind Japan Phase 3 Study for Roxadustat in Hemodialysis Chronic Kidney Disease Patients with Anemia

TOKYO and San Francisco, May 31, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and FibroGen, Inc. (Nasdaq: FGEN, CEO: Thomas B. Neff, “FibroGen”

Read more
May 31, 2018

Astellas Oncology C3 Prize® Returns for Third Year with Focus on Improving -Cancer Care in Underserved Regions of the World-

TOKYO – May 31, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced the launch of the third annual Astellas Oncology C3 Prize...

Read more
May 29, 2018

U.S. FDA Grants Priority Review to Astellas’ New Drug Application for Gilteritinib for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

TOKYO – May 29, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. “Astellas”) announced today that the U.S. Food and Drug Administration (FDA) has accepted,...

Read more
May 24, 2018

Addition of Mirabegron to Tamsulosin Demonstrates Superior Efficacy Compared to Placebo in Men with Overactive Bladder Symptoms

TOKYO – May 24, 2018 – Astellas Pharma Inc. (President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that the post-marketing MATCH study exploring use of mirabegron versus...

Read more
May 22, 2018

SUJANU® Combination Tablets released -Drug combining selective DPP-4 inhibitor and selective SGLT2 inhibitor-

Tokyo,May 22,2018 -MSD K.K. (head office: Chiyoda-ku, Tokyo; President: Jannie Oosthuizen; “MSD”) and Astellas Pharma Inc. (head office: Chuo-ku, Tokyo; President and CEO; Kenji Yasukawa;...

Read more
May 22, 2018

Restructuring of Operations in Japan - Restructuring Astellas Pharma Inc. and group companies in Japan, and offering early retirement incentive program -

TOKYO, May 22, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced restructuring of operations in Japan and introduction of the early...

Read more
May 16, 2018

Astellas Announces Abstracts Highlighting Growing Oncology Portfolio to be Presented at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

TOKYO – May 16, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that a wide selection of abstracts highlighting the...

Read more
May 11, 2018

Partial Amendments to the Articles of Incorporation

Read more
May 11, 2018

Notice Regarding the Performance-linked Stock Compensation Scheme

Read more
May 10, 2018

Aquinox and Astellas Announce Exclusive Licensing Agreement for Rosiptor in the Asia-Pacific Region Including Japan

VANCOUVER, British Columbia, May 9, 2018 and TOKYO, Japan, May 10, 2018 – Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP, “Aquinox”), a clinical-stage pharmaceutical company discovering and...

Read more
May 8, 2018

FDA Approves Supplemental New Drug Application for Myrbetriq® (mirabegron) for Use in Combination with solifenacin succinate for the Treatment of Overactive Bladder Symptoms

TOKYO, May 7, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that the U.S. Food and Drug Administration (FDA) has approved a...

Read more
Apr 26, 2018

Astellas Announces Cancellation of Treasury Shares

Read more
Apr 26, 2018

Astellas Reports Financial Results for FY2017

Read more
Apr 26, 2018

Astellas Announces Director Candidates after the Transition to a Company with an Audit & Supervisory Committee

Read more
Apr 24, 2018

Astellas Submits New Drug Applications for Approval of Gilteritinib for the Treatment of FLT3mut+ Relapsed or Refractory Acute Myeloid Leukemia

TOKYO, April 24, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that it submitted on March 23, 2018, a new drug application...

Read more
Apr 18, 2018

Astellas Announces Sale of Certain Agensys Research Facilities to Kite, a Gilead Company

TOKYO, April 18, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, “Astellas” ) and Kite, a Gilead Company (Nasdaq: GILD, President and CEO: John Milligan, “Kite”)...

Read more
Mar 29, 2018

Astellas to Participate in “Neglected Tropical Diseases Drug Discovery Booster” Consortium with DNDi and Seven Other Pharmaceutical Companies

Tokyo, March 29, 2018 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced an agreement for collaborative research with the Drugs for Neglected Diseases...

Read more
Mar 28, 2018

Astellas Announces Personnel Change

Astellas Announces Personnel Change

Read more
Mar 27, 2018

Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer

TOKYO and BOTHELL, Wash., – March 26, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced...

Read more
Mar 26, 2018

Notice of Completion of Acquisition of Own Shares

Tokyo, March 26, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “the Company”) announced that it completed acquisition of its own shares, which was resolved by...

Read more
Mar 23, 2018

SUJANU® Combination Tablets combining type-2 diabetes drugs receive marketing approval in Japan

Read more
Mar 22, 2018

Astellas Receives Orphan Drug Designation from the Japanese MHLW for Gilteritinib

Tokyo, March 22, 2018 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted...

Read more
Mar 19, 2018

U.S. FDA Grants Priority Review for a Supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) in Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

sNDA Seeks to Expand the Indication of XTANDI to include Men with Non-metastatic CRPC

NEW YORK and TOKYO, March 19, 2018 – Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that a supplemental New...

Read more
Mar 16, 2018

European Medicines Agency Accepts Type II Variation Application Filing for XTANDITM (enzalutamide) In Non-Metastatic Castration-resistant Prostate Cancer

TOKYO – March 16, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that the European Medicines Agency (EMA) has validated and...

Read more
Mar 15, 2018

Astellas Announces Personnel Change

Astellas Announces Personnel Change

Read more
Mar 9, 2018

Astellas Received Approval for Solifenacin Oral Suspension for Pediatric Patients in Europe

Tokyo, March 9, 2018 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that solifenacin succinate (generic name, “solifenacin”) oral suspension...

Read more
Mar 6, 2018

Tottori University and Astellas Enter into the Global Exclusive Licensing Agreements for Immunostimulating Gene Loading Oncolytic Virus

Tottori and Tokyo, March 6, 2018 - Tottori University (President: Ryota Teshima, “Tottori University”) and Astellas Pharma Inc. (TSE:4503, President and CEO: Yoshihiko Hatanaka,...

Read more
Mar 2, 2018

Astellas Announces Status of Acquisition of Own Shares

Read more
Mar 1, 2018

Astellas Receives Approval for XTANDI Tablets, a Treatment for Castration-Resistant Prostate Cancer, in Japan

Tokyo, March 1, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that 40 mg XTANDI Tablets and 80 mg XTANDI Tablets received...

Read more
Feb 16, 2018

Astellas Launches Global Campaign in Collaboration with CNN as Part of Global Corporate Brand Activity

- Sponsors Tomorrow’s Hero in February and March 2018. : Tomorrow’s Hero showcases young innovators who are transforming the world for a brighter future -

Tokyo, February 16, 2018 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) launched “CNN Tomorrow’s Hero” as a part of its global corporate brand campaign which...

Read more
Feb 14, 2018

Astellas Partners with Discovery Communications for its Global Branding Campaign

Read more
Feb 14, 2018

Astellas Acquires Universal Cells, Inc.

- Acquisition enables Astellas to fully utilize proprietary technology to produce pluripotent stem cells that have the potential to lower immunological rejection in numerous therapeutic areas -

Tokyo, February 13, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Universal Cells, Inc. (CEO: Claudia Mitchell, “Universal Cells”) today...

Read more
Feb 8, 2018

Astellas Announce Top-Line Results for Two Phase 3 Trials of Peficitinib in Rheumatoid Arthritis Patients with Inadequate Response to Existing Therapy

Tokyo, February 8, 2018 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that the results of two Phase 3 trials (RAJ3 and RAJ4 trials) on Peficitinib...

Read more
Feb 5, 2018

Astellas Announces Changes in Management Structure, Global Function, and Top Management Committees

Read more
Feb 5, 2018

Astellas Announces Personnel Changes and Organizational Changes

Astellas Announces Personnel Changes and Organizational Changes

Read more
Feb 5, 2018

Phase 3 PROSPER Trial Shows XTANDI® (enzalutamide) Significantly Reduced the Risk of Metastasis or Death by 71 Percent in Men with Non-Metastatic Castration-Resistant Prostate Cancer

Pfizer Contacts: For Media Sally Beatty 212-733-6566 sally.beatty@pfizer.com For Investors Ryan Crowe 212-733-8160 ryan.crowe@pfizer.com Astellas Contacts: For Media Tarsis Lopez 847-224-8374...

Read more
Jan 31, 2018

Astellas Announces Transition to a Company with an Audit & Supervisory Committee

Tokyo, January 31, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that, at a meeting of the Board of Directors held today, it...

Read more
Jan 31, 2018

Astellas Announces Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act) Tokyo, January 31, 2018 - Astellas Pharma Inc. (TSE: 4503, President and...

Read more
Jan 31, 2018

Astellas Appoints Kenji Yasukawa as President and CEO

- Yasukawa, who brings more than 30 years of experience in the pharmaceutical industry, succeeds Yoshihiko Hatanaka, who will become Chairman of the Board -

Tokyo, January 31, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “the Company” ) today announced that its Board of Directors approved a change in its...

Read more
Jan 29, 2018

Astellas to Present New Oncology Data at the 2018 ASCO Genitourinary Cancers (GU) Symposium

– A total of 10 abstracts and one trial in progress (TIP) across various cancers to be presented during oral and poster sessions –

TOKYO – January 26, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced new data to be presented at the 2018 Genitourinary Cancers...

Read more
Jan 24, 2018

Astellas Completes Acquisition of Mitobridge, Inc.

Tokyo, Janurary 24, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that it has completed the acquisition of Mitobridge, Inc....

Read more
Jan 23, 2018

Astellas Receives Orphan Designation from the European Commission for Gilteritinib for the Treatment of Acute Myeloid Leukaemia

TOKYO – January 23, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that the European Commission (EC) has issued Orphan...

Read more
Jan 22, 2018

Astellas and Vical Announce Top-Line Results for Phase 3 Trial of Cytomegalovirus Vaccine ASP0113 in Hematopoietic Stem Cell Transplant Recipients

TOKYO and SAN DIEGO – Jan. 22, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Vical Incorporated (NASDAQ: VICL) announced today that...

Read more
Jan 12, 2018

Repatha® SC Injection 420 mg Auto Mini Doser Launched in Japan

Amgen Astellas BioPharma K.K. (Headquarters, Tokyo; President and Representative Director: Steve Sugino, “Amgen Astellas”) and Astellas Pharma Inc. (Headquarters, Tokyo; President and CEO:...

Read more
Jan 11, 2018

Astellas Submits Supplemental New Drug Application for Approval of Additional Indication of Selective SGLT2 Inhibitor Ipragliflozin L-Proline for Patients with Type 1 Diabetes Mellitus in Japan

Tokyo and City, January 11, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) and Kotobuki Pharmaceutical Co., Ltd. (President and CEO; Hiroshi...

Read more
Jan 9, 2018

Application for Marketing Approval Submitted for Bispecific CD19-directed CD3 T Cell Engager (BiTE® ) Antibody Construct Blinatumomab for Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia in Japan

TOKYO (January 9, 2018) - Amgen Astellas BioPharma K.K. (Headquarters Tokyo; President and Representative Director Steve Sugino “Amgen Astellas BioPharma”) and Astellas Pharma Inc....

Read more
Dec 20, 2017

Astellas to Present at J.P. Morgan Healthcare Conference

Tokyo, December 20, 2017 - Astellas Pharma Inc. today announced that the company's President and CEO Yoshihiko Hatanaka will present at the 36 th Annual J.P. Morgan Healthcare Conference on...

Read more
Dec 11, 2017

Astellas Announces First Clinical Data from Phase I Study of Gilteritinib in Combination with Intensive Chemotherapy in Patients Newly Diagnosed with Acute Myeloid Leukemia

TOKYO – December 11, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today the first reported data of the investigational agent...

Read more
Dec 6, 2017

Astellas, the Institute of Medical Science of the University of Tokyo, Chiba University, and Asahi Kogyosha Enter into Collaborative Research Agreement on Rice-based Oral Vaccine “MucoRice”

Tokyo, December 6, 2017 - Astellas Pharma Inc. (Tokyo, President and CEO: Yoshihiko Hatanaka, “Astellas” ), the Institute of Medical Science, the University of Tokyo (Tokyo, Dean: Yoshinori...

Read more
Dec 1, 2017

Astellas Acquires Mitobridge Under Existing Collaboration

-Accelerating the Discovery and Development of Novel Drugs that Target Mitochondrial Functions -

Tokyo and Cambridge, November 30, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Mitobridge, Inc.1 (President and CEO: Kazumi Shiosaki,...

Read more
Dec 1, 2017

Astellas Announces Personnel Change

Read more
Nov 30, 2017

Astellas Submits a New Drug Application for Gonax® 12-Week Extended-Release Formulation for Treatment of Prostate Cancer in Japan

Tokyo, November 30, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that that it submitted an application for marketing approval in...

Read more
Nov 29, 2017

Astellas to Present New Data Exploring Gilteritinib in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients at the 2017 American Society of Hematology Annual Meeting (ASH)

– A breadth of abstracts highlighting the acute myeloid leukemia treatment landscape, healthcare resource use and cost of care to be presented during oral and poster sessions –

TOKYO – November 28, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced new data in acute myeloid leukemia (AML) research, including...

Read more
Nov 28, 2017

MSD and Astellas conclude co-promotion agreement in Japan for type 2 diabetes combination drug

Drug combining selective DPP-4 inhibitor and selective SGLT2 inhibitor

Tokyo, November 28, 2017 -MSD K.K. (President: Jannie Oosthuizen; “MSD”) and Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka; “Astellas”) today announced that they have...

Read more
Nov 8, 2017

Astellas and Seattle Genetics Initiate Phase 1b Trial of Enfortumab Vedotin in Combination with Immune Checkpoint Inhibitor Therapies in Locally Advanced or Metastatic Urothelial Cancer

Read more
Oct 31, 2017

Astellas and FibroGen Announce Positive Topline Results from First Japan Phase 3 Trial for Roxadustat in Chronic Kidney Disease Patients with Anemia

Tokyo and San Francisco, October 31, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and FibroGen, Inc. (Nasdaq: FGEN, CEO: Thomas B. Neff,...

Read more
Oct 30, 2017

Extension of Agreement Pertaining to Sale of Telmisartan (Micardis® family)

Tokyo, October 30, 2017 – Nippon Boehringer Ingelheim Co., Ltd. (President and Representative Director: Yoshiaki Aono, “Nippon Boehringer Ingelheim”) and Astellas Pharma Inc. (President and...

Read more
Oct 30, 2017

Astellas Enters into a Screening Collaboration Agreement with MMV to Discover Antimalarial Drugs

Tokyo, October 30, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that it has entered into a screening collaboration agreement with Medicines...

Read more
Oct 20, 2017

Astellas and Universal Cells, Inc. Announce a Collaboration Utilizing Universal Donor Cell Technology

Tokyo, October 19, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Universal Cells, Inc. (CEO: Claudia Mitchell, “Universal Cells”) today...

Read more
Oct 18, 2017

Astellas Enters into a New Collaborative Research Agreement with TB Alliance to Discover Anti- tuberculosis Drugs

Tokyo, October 18, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that it has entered into a new collaborative research agreement with TB...

Read more
Oct 11, 2017

Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Conduct “JOINUS,” a New Drug Discovery Program Using Drug-Repositioning Compound Library

- Three Japanese pharmaceutical companies collaborate in facilitating drug discovery in Japan through open innovation sharing of compounds developed by the companies-

Tokyo and Osaka, October 11, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka; Headquarters: Tokyo; TSE: 4503; “Astellas” ), Mitsubishi Tanabe Pharma Corporation (President...

Read more
Oct 11, 2017

Astellas and Seattle Genetics Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer

Solid Tumor Antibody-Drug Conjugate (ADC) Enfortumab Vedotin to be Evaluated as a Monotherapy in Patients Previously Treated with a Checkpoint Inhibitor

TOKYO and BOTHELL, Wash., October 10, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Seattle Genetics Inc., Inc., (NASDAQ: SGEN) today announced...

Read more
Oct 11, 2017

U.S. FDA Grants Fast Track Designation to Astellas for Development of Gilteritinib in Relapsed or Refractory Acute Myeloid Leukemia

TOKYO – October 11, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that the U.S. Food and Drug Administration (FDA) has granted...

Read more
Oct 2, 2017

Astellas Announces Status of Acquisition of Own Shares

Read more
Oct 2, 2017

Astellas and TOA EIYO Announce Co-promotion Agreement for Kiklin® Capsules 250mg and Kiklin® Granules 86.2%

Astellas Pharm Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and TOA EIYO LTD. (President: Atsuo Takahashi, “TOA EIYO”) announced that the companies have entered into...

Read more
Sep 14, 2017

Pfizer and Astellas Announce Positive Top-Line Results from Phase 3 PROSPER Trial of XTANDI (enzalutamide) in Patients with Non-Metastatic Castration-Resistant Prostate Cancer

Pfizer Contacts: For Media Sally Beatty (212) 733-6566 sally.beatty@pfizer.com For Investors Chuck Triano (212) 733-3901 charles.e.triano@pfizer.com Astellas Contact: For Media Tyler Marciniak...

Read more
Sep 13, 2017

U.S. FDA Accepts for Review Astellas’ Supplemental New Drug Application for mirabegron for Use in Combination with solifenacin succinate 5 mg for the Treatment of Overactive Bladder

If approved, the combination therapy could potentially offer a new treatment option for patients whose overactive bladder symptoms are not adequately controlled on monotherapy

Tokyo, Sept. 12, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that the U.S. Food and Drug Administration (FDA) has accepted for...

Read more
Sep 11, 2017

Astellas Submits Supplemental New Drug Application for Approval of Additional Indication of “Linaclotide" for Patients with Chronic Constipation in Japan

Tokyo, September 11, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that it has submitted a supplemental new drug application for...

Read more
Sep 1, 2017

Astellas Announces Status of Acquisition of Own Shares

Read more
Aug 30, 2017

Repatha® Receives Approval for New 420mg Single-Dose Delivery Option in Japan

TOKYO (August 30, 2017) – Amgen Astellas BioPharma K.K. (Headquarters, Tokyo; President and Representative Director: Steve Sugino, “Amgen Astellas”) and Astellas Pharma Inc. (Headquarters,...

Read more
Aug 24, 2017

Astellas Announces Personnel Changes and Organizational Changes

Read more
Aug 22, 2017

First Patient Dosed in Phase 3 MORPHO Trial Evaluating Gilteritinib as Maintenance Therapy Following Hematopoietic Stem Cell Transplantin Patients with FLT3 Mutation-positive Acute Myeloid Leukemia

TOKYO – August 22, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that the first patient was dosed in the registrational Phase 3...

Read more
Aug 1, 2017

Astellas Announces Status of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act) Tokyo, August 1, 2017- Astellas Pharma Inc. (TSE: 4503, President and CEO:...

Read more
Aug 1, 2017

LTL Pharma Succeeds Marketing Approval for “Nivadil® Tablets”, “Solantal® Tablets” and “Lowgan® Tablets”, and is Transferred Distribution Rights in Japan

Tokyo (Japan), August 1, 2017 –LTL Pharma Co., Ltd. (Representative Director, Chairman: Sansei Oka, Representative Director, President: Jiro Mizukawa, “LTL Pharma”) and Astellas Pharma Inc....

Read more
Jul 31, 2017

Astellas Submits Application for Approval of fidaxomicin for the Treatment of Infectious Enteritis Caused by Clostridium difficile in Japan

Tokyo, July 31, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it has submitted an application for marketing approval of...

Read more

Show per page

Discover more

Media contacts

Return to media homepage

Subscribe to news alerts

Choose Language

News